• Zamawiaj do paczkomatu
  • Płać wygodnie
  • Obniżka
Advances in Studies on Enzyme Inhibitors as Drugs: Volume 1: Anticancer & Antiviral Drugs

Advances in Studies on Enzyme Inhibitors as Drugs: Volume 1: Anticancer & Antiviral Drugs

9781536105049
1 385,94 zł
1 247,34 zł Zniżka 138,60 zł Brutto
Najniższa cena w okresie 30 dni przed promocją: 1 247,34 zł
Ilość
Produkt niedostępny
Nakład wyczerpany (niedostępny u wydawcy)

  Dostawa

Wybierz Paczkomat Inpost, Orlen Paczkę, DPD, Pocztę, email (dla ebooków). Kliknij po więcej

  Płatność

Zapłać szybkim przelewem, kartą płatniczą lub za pobraniem. Kliknij po więcej szczegółów

  Zwroty

Jeżeli jesteś konsumentem możesz zwrócić towar w ciągu 14 dni*. Kliknij po więcej szczegółów

Opis
This book which is edited by eminent scientist Satya P. Gupta, covers the most recent development on design and discovery of the most useful drugs acting against several life threatening diseases such as cancer, viral infections and many others in two volumes. All of these drugs are based on inhibitions of various enzymes. Most human diseases are found to be associated with the overexpression of the enzymes. The book presents the structural aspects of various enzymes, their active sites, and the structural requirements of chemicals for strong interactions with enzymes. Volume One contains twelve chapters related to enzyme inhibitors acting as anticancer and antiviral drugs (each written by highly acclaimed authors), and Volume Two contains ten chapters on enzyme inhibitors acting against miscellaneous diseases written by equally competent authors. The book may be an asset for drug industries, research organisations, and individual researchers.
Szczegóły produktu
72326
9781536105049
9781536105049

Opis

Rok wydania
2017
Numer wydania
1
Oprawa
twarda
Liczba stron
340
Wymiary (mm)
180.00 x 260.00
Waga (g)
818
  • Preface; Mitogen-Activated Protein Kinase (MAPK) Inhibitors for The Treatment of Advanced Hepatocellular Carcinoma; Protein Farnesyltransferase Inhibitors as Novel Anticancer Chemotherapeutics; Peptidylarginine Deiminase (PAD) Inhibitors; Interfering with Enzymatic Steps of Micrornas Pathway Using Small Molecules; In Silico Studies for the Discovery of Leads to Inhibit Cyclin-Dependent Kinase 2 (CDK2); Design & Development of Tyrosine Kinase Inhibitors as Anticancer Drugs; In Silico Design of Carbonic Anhydrase Inhibitors as Antitumor Drugs; Studies on Inhibitors of Dengue Virus Protease; Design & Development of Inhibitors of Picornavirus Proteases; Neuraminidase Inhibitors: From Research Tools to Drug Candidates; Recent Developments in HIV-1 Integrase Inhibitors; Studies on Dual Inhibitors of HIV Reverse Transcriptase & Integrase; Index.
Komentarze (0)